


RESEARCH

Open Access



International practices in the dietary management of fructose 1-6 biphosphatase deficiency

A. Pinto^{1*} , M. Alfadhel², R. Akroyd³, Y. Atik Altinok⁴, S. M. Bernabei⁵, L. Bernstein⁶, G. Bruni⁷, G. Caine⁸, E. Cameron⁹, R. Carruthers¹⁰, B. Cochrane¹¹, A. Daly¹, F. de Boer¹², S. Delaunay¹³, A. Dianin¹⁴, M. Dixon¹⁵, E. Drogari¹⁶, S. Dubois¹⁷, S. Evans¹, J. Gribben¹⁸, G. Gugelmo¹⁴, C. Heidenborg¹⁹, I. Hunjan²⁰, I. L. Kok²¹, B. Kumru²², A. Liguori⁵, D. Mayr²³, E. Megdad²⁴, U. Meyer²⁵, R. B. Oliveira²⁶, A. Pal²⁷, A. Pozzoli²⁸, R. Pretese²⁹, J. C. Rocha^{30,31,32,33}, S. Rosenbaum-Fabian³⁴, J. Serrano-Nieto³⁵, E. Sjoqvist³⁶, C. Timmer³⁷, L. White³⁸, T. van den Hurk²¹, M. van Rijn¹², H. Zweers³⁹, M. Ziadlou⁴⁰ and A. MacDonald¹

Abstract

Background: In fructose 1,6 biphosphatase (FBPase) deficiency, management aims to prevent hypoglycaemia and lactic acidosis by avoiding prolonged fasting, particularly during febrile illness. Although the need for an emergency regimen to avoid metabolic decompensation is well established at times of illness, there is uncertainty about the need for other dietary management strategies such as sucrose or fructose restriction. We assessed international differences in the dietary management of FBPase deficiency.

Methods: A cross-sectional questionnaire (13 questions) was emailed to all members of the Society for the Study of Inborn Errors of Metabolism (SSIEM) and a wide database of inherited metabolic disorder dietitians.

Results: Thirty-six centres reported the dietary prescriptions of 126 patients with FBPase deficiency. Patients' age at questionnaire completion was: 1-10y, 46% ($n = 58$), 11-16y, 21% ($n = 27$), and >16y, 33% ($n = 41$). Diagnostic age was: <1y, 36% ($n = 46$); 1-10y, 59% ($n = 74$); 11-16y, 3% ($n = 4$); and >16y, 2% ($n = 2$). Seventy-five per cent of centres advocated dietary restrictions. This included restriction of: high sucrose foods only ($n = 7$ centres, 19%); fruit and sugary foods ($n = 4$, 11%); fruit, vegetables and sugary foods ($n = 13$, 36%). Twenty-five per cent of centres ($n = 9$), advised no dietary restrictions when patients were well. A higher percentage of patients aged >16y rather than $\leq 16y$ were prescribed dietary restrictions: patients aged 1-10y, 67% ($n = 39/58$), 11-16y, 63% ($n = 17/27$) and >16y, 85% ($n = 35/41$). Patients classified as having a normal fasting tolerance increased with age from 30% in 1-10y, to 36% in 11-16y, and 58% in >16y, but it was unclear if fasting tolerance was biochemically proven. Twenty centres (56%) routinely prescribed uncooked cornstarch (UCCS) to limit overnight fasting in 47 patients regardless of their actual fasting tolerance (37%). All centres advocated an emergency regimen mainly based on glucose polymer for illness management.

Conclusions: Although all patients were prescribed an emergency regimen for illness, use of sucrose and fructose restricted diets with UCCS supplementation varied widely. Restrictions did not relax with age. International guidelines are necessary to help direct future dietary management of FBPase deficiency.

Keywords: Fructose 1,6 biphosphatase deficiency, Dietary restrictions, Fasting tolerance, Uncooked cornstarch

* Correspondence: alex.pinto@nhs.net

¹Birmingham Women's and Children's Hospital, Birmingham, UK
Full list of author information is available at the end of the article

Background

Fructose 1, 6 bisphosphatase (FBPase) deficiency (OMIM #229700), is a rare, autosomal recessive inherited disorder of gluconeogenesis [1]. It was first described by Baker and Winegrad in 1970 [2], who found recurrent episodes of hypoglycaemia and lactic acidosis in a 5-year-old girl; her elder brother died at the age of 6 months following severe metabolic acidosis probably with the same condition [2]. FBPase is a key gluconeogenic enzyme that irreversibly catalyses the hydrolysis of fructose-1,6-bisphosphate to fructose-6-phosphate and inorganic phosphate [3]. Its inactivity prevents the endogenous formation of glucose from precursors including lactate, glycerol, fructose, and gluconeogenic amino acids such as alanine [4]. Consequently alanine, lactate, glycerol, glycerol-3-phosphate and ketones [5] accumulate during fasting. Hypoglycaemia occurs after prolonged fasting when glycogen stores are depleted [3]. FBPase incidence is unknown, but is possibly between 1: 350,000 and <1: 900,000 in Europe [1, 6]. Cases have also been identified in Japan [3], China, USA [7], Israel [8], Turkey [9], Morocco, and Saudi Arabia [10]. Incidence is higher in countries with greater rates of consanguinity [11].

Clinical presentation may be as early as 1-4 days of life, when glycogen stores are limited, and is associated with a high mortality [6], but many children experience recurrent acute episodes before diagnosis is made [4]. Symptoms include hypoglycaemia, metabolic acidosis, lactic acidosis, ketonuria, apnoea, seizures, severe hyperventilation, hypotonia, and moderate hepatomegaly [12, 13], usually accompanying prolonged fasting associated with illness [14].

Dietary management is not well characterised. Management aims to prevent hypoglycemia and lactic acidosis by avoiding prolonged fasting and excessive intake of fructose and sucrose, particularly in young children. Although fructose is a gluconeogenic precursor, the severity or need for sucrose and fructose restriction remains indeterminate. It is often reported that fasting should not exceed 8 h, but it is accepted that fasting tolerance improves with age [2, 15]. It is unclear if dietary strategies such as the use of uncooked cornstarch (UCCS) to limit overnight fasting is necessary or even effective. Treatment of metabolic decompensation with oral or intravenous glucose \pm sodium bicarbonate is essential. Between episodes of acute metabolic decompensation, patients usually remain well and it is considered a benign condition once diagnosis and management is established [4, 16].

Due to the rarity of the disorder, few metabolic centres manage more than 10 patients. In order to try and understand long-term dietary prescriptions in FBPase deficiency, we have identified the differences in dietary management of a large international patient cohort.

Methods

A cross sectional questionnaire (power point document) was sent to all members of the Society for the Study of Inborn Errors of Metabolism (SSIEM) by email as well as an extensive database of IMD dietetic colleagues ($n = 250$) who have collaborated on previous surveys [17, 18].

The questionnaire was comprised of 13 open and multiple-choice questions about dietary practices in FBPase deficiency. Information on: number of patients, ethnicity, age at diagnosis, dietary restrictions, UCCS, fasting tolerance and emergency regimens was collected. Questionnaire responses were divided by geographical region in order to analyse for any effect on dietary practices. Ethical consent was not sought as outcome data and patient identifiable data was not obtained. Data was analysed using descriptive statistics only.

Results

Participants

Thirty-six international IMD centres from 15 countries returned questionnaires, reporting 126 patients with FBPase deficiency. The majority of responses were from dietitians (92%, $n = 36$) with a minority from physicians (8%, $n = 3$). Forty-five patients were Caucasian, 38 Arabic and 27 Asian (23 Pakistani and 4 Bangladeshi). The remaining 16 patients belonged to other ethnicities that were not identified. There was a median of 2 (1-24) patients per centre.

The centres were divided into the following geographical regions: Western Europe: 9 centres caring for $n = 18$ patients (Austria [$n = 1$], France [$n = 6$], Germany [$n = 2$] and The Netherlands [$n = 9$]); Southern Europe: 9 centres caring for $n = 35$ patients (Greece [$n = 8$], Italy [$n = 13$], Spain [$n = 1$] and Turkey [$n = 13$]); Northern Europe: 12 centres caring for $n = 41$ patients (Sweden [$n = 3$] and United Kingdom [$n = 38$]), and non-Europe: 6 centres caring for $n = 32$ patients (Iran [$n = 3$], Saudi Arabia [$n = 25$], Brazil [$n = 2$], United States of America [$n = 1$] and New Zealand [$n = 1$]).

Patient's age at diagnosis was: < 1y, 36% ($n = 46$); 1-10y, 59% ($n = 74$), 11-16y, 3% ($n = 4$), and >16, 2% ($n = 2$). Patients were diagnosed in adulthood in Brazil and USA. Data was not collected on age of first clinical symptoms although several centres commented there was a delay between age of presentation and diagnostic age. At the time of questionnaire completion, patient age was categorised into the following groups: 46% ($n = 58$) 1-10y, 21% ($n = 27$) 11-16y; and 33% ($n = 41$) >16y.

Dietary restrictions when well (Table 1)

Most patients in 75% of centres ($n = 27/36$) were prescribed sucrose or fructose restrictions; 7 centres restricted high sucrose foods only ($n = 17$ patients), 4 centres (30 patients) restricted sugary foods and fruits

Table 1 Number of patients prescribed each dietary restriction by geographical region

Geographical region (Number of centres)	Patient number (n)			
	No dietary restriction	Sugary foods, fruit and vegetables restriction	Sugary foods and fruit restriction	Only sugary foods restriction
Western Europe (n = 18)	3	9	5	1
Southern Europe (n = 35)	3	19	0	13
Northern Europe (n = 41)	28	11	1	1
Non-Europe (n = 32)	1	5	24	2
Totals (n = 126)	35	44	30	17

only and 13 centres (n = 44 patients) restricted fruits, vegetables and sugary foods. In 3 centres (9 patients), dietary prescription varied according to clinical signs and symptoms. Three centres from Western Europe, Northern Europe and Non-Europe calculated fructose amounts. More adults than children were prescribed dietary restrictions (age 1-10y, 67% [n = 39/58], 11-16y, 63% [n = 17/27] and >16y, 85% [n = 35/41]).

Twenty-five percent of centres (n = 9, 35 patients) did not advocate any dietary restrictions when well. Nineteen patients were aged 1-10y, 10 aged 11-16y and 6 patients aged >16y. Dietary restrictions by geographical region are shown in Table 1. One patient was tube fed due to comorbidities.

Fasting tolerance and use of uncooked cornstarch

Professionals reported fasting tolerance in 112 (89%) patients, but it was unclear on what criteria this was established. Fasting tolerance improved with age, with the number of patients with reported normal fasting tolerance in each age group increasing from 30% (n = 14/47) in 1-10y, to 36% (n = 9/25) in 11-16y and 58% (n = 23/40) in >16y. Twenty (56%) centres (Table 2) routinely prescribed UCCS to extend overnight fasting, which represented 37% (n = 47/126) of all patients; but still most patients (n = 79) were managed without UCCS prescription. In the 47 patients prescribed UCCS, the mean dose (g/kg/dose) for the group was 1.1 and by age category was aged 1-10y (n = 30), 1.2; 11-16y (n = 7); 1.3; >16y (n = 10), 1.0. Figure 1 shows the mean amount of

Table 2 Number of centres prescribing uncooked cornstarch by geographical region

Geographical region (Number of centres)	Number of centres (n)	
	Number of centres prescribing uncooked cornstarch	Number of centres not prescribing uncooked cornstarch
Western Europe (n = 9)	4	5
Southern Europe (n = 9)	8	1
Northern Europe (n = 12)	5	7
Non-Europe (n = 6)	3	3
Totals (n = 36)	20	16

UCCS dose given in each age range in centres from different geographical regions. Two centres prescribed Glycosade (VitaFlo®), a slow release starch. Other complex carbohydrates such as cereals, bread, rice or pasta were encouraged as alternatives to UCCS before bedtime.

Sixteen centres (n = 53 patients) did not use UCCS before overnight fasting (7 centres from Northern Europe, 5 centres from Western Europe, 3 non-European centres [including 24 patients from one centre] and 1 centre from Southern Europe). In patients prescribed UCCS (data available in 36 out of 47 patients), 36% (n = 13) of centres reported a fasting tolerance <10 h and 64% (n = 23) a fasting tolerance >10 h when well. When fasting tolerance was <10 h, the median amount of UCCS given prior to fasting was 1 g/kg (n = 13 patients); the same amount of UCCS was given when fasting tolerance was ≥10 h (n = 23 patients). Figure 2 shows the mean dose of UCCS given when fasting is <10 h and >10 h per patient. We did not collect biochemical evidence of fasting tolerance, so it was unclear how respondents determined this or when it was last estimated in individual patients.

Dietary management when unwell

All centres prescribed an emergency regimen using glucose polymer during illness. The median % glucose concentration from glucose polymer used in emergency feeds during illness was 10% (10-15%) for infants aged 0-12 months; 15% (10-23%) for children aged 1-2y; 20% (10-25%) for children aged 3-10y and 25% (10-30%) in patients over >10y. Only 2 centres used fructose sources such as fruit juice or fruit squash to flavour glucose polymer when glucose polymer was refused. Extra glucose polymer was used in the recovery period in 21 out of 36 centres (58%). Twenty-seven centres (75%) reported that patients accepted oral glucose polymer for their emergency regimen. When it was refused, admission to hospital for IV fluids was advocated.

Discussion

This is the first paper reporting the dietary management of 126 patients with FBPase deficiency from 36 international centres. With the exception of emergency regimens based on glucose polymer, dietary treatment was

and fructose dietary restrictions and the use of UCCS varied widely and particularly in older patients it may be unnecessary. International guidelines on management would optimise dietary treatment preventing any unnecessary over restriction and risk of nutritional deficiencies but also maintaining patient's safety, which is the primary objective.

Abbreviations

FBPase: Fructose 1,6 biphosphatase; GSD: Glycogen storage disease; SSIEM: Society for the Study of Inborn Errors of Metabolism; UCCS: Uncooked cornstarch

Acknowledgments

The authors would like to thank the following people for the assistance in data collection: Camille Newby and Diana Webster (Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, UK); Beatriz Jurkiewicz Frangipani (Centro de Referência em Erros Inatos do Metabolismo, Universidade Federal de São Paulo, São Paulo, Brasil); Serena Tursi (Fondazione MBBM, San Gerardo Hospital, Monza, Italy); Kate Billmore (Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK); Elena Banci and Fina Belli (Azienda Ospedaliero Universitaria Meyer, Firenze, Italy); Murielle Assoun and Claire Belloche (Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France); Suhad Al Maigel, Bedour Handoom, Dana Al Qasabi and Munirah Al Mesned (Metabolic Nutrition Clinics. King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia); and Sarah Grünert (University Children's Hospital Freiburg, Germany).

This article was supported by ERDF through the operation POCL-01-0145-FEDER-007746 funded by the Programa Operacional Competitividade e Internacionalização – COMPETE2020 and by National Funds through FCT - Fundação para a Ciência e a Tecnologia within CINTESIS, R&D Unit (reference UID/IC/4255/2013).

Funding

Funding was not needed to develop this study.

Availability of data and materials

The datasets used and/or analyzed during this current study are available from the corresponding author upon request.

Authors' contributions

AP, AD, SE, JCR and AM developed the questionnaire and helped draft the manuscript. All authors were involved in data collection, interpretation of data and critical revision of the paper for important intellectual content and final approval of the version to be published.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Alex Pinto has received an educational grant from Cambrooke Therapeutics and grants from Vitaflor, Nutricia, Merck Serono and Biomarin to attend scientific meetings. Anne Daly has undertaken evaluation work for the nutritional companies – Vitaflor Ltd., Nutricia Ltd. and Metax. Sharon Evans is a research dietician funded by Nutricia; financial support from Nutricia and Vitaflor to attend study days and conferences. Júlio César Rocha is member of the European Nutrition Expert Panel (Biomarin) and member of an Advisory Board for Applied Pharma Research. Anita MacDonald has received research funding and honoraria from Nutricia, Vitaflor International and Merck Serono. She is a member of the European Nutrition Expert Panel (Biomarin), member of Sapropterin Advisory Board (Biomarin), member of the Advisory Board entitled ELEMENT (Danone-Nutricia), and member of an Advisory Board for Arla and Applied Pharma Research. Joanna Gribben has undertaken evaluation work for the nutritional companies – Vitaflor Ltd. and Nutricia Ltd. She has had financial support from Nutricia and Vitaflor to attend study days and conferences. Rhonda Akroyd has received financial support from Nutricia, Menarini, Shire and Vitaflor to attend study days and scientific meetings. Barbara Cochrane has undertaken evaluation work for the nutritional companies – Vitaflor Ltd. and Nutricia Ltd. She has had

financial support from Nutricia and Vitaflor to attend study days and conferences. Corrie Timmer has received support from Nutricia and Vitaflor to attend scientific meetings. Marjorie Dixon has received research funding and honoraria from Nutricia, Vitaflor and is a member of the Nutricia Advisory Board.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Birmingham Women's and Children's Hospital, Birmingham, UK. ²King Abdullah International Medical Research Centre, King Saud bin Abdulaziz University for Health Sciences, Genetic Division, Department of Pediatrics, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs (NGHA), Riyadh, Saudi Arabia. ³National Metabolic Service, Starship Child Health and Auckland City Hospital, Auckland, New Zealand. ⁴Pediatric Metabolism Department, Ege University Medical Faculty, Izmir, Turkey. ⁵Children's Hospital Bambino Gesù, Division of Artificial Nutrition, Rome, Italy. ⁶IMD Nutrition, Children's Hospital Colorado, Aurora, CO, USA. ⁷Azienda Ospedaliero Universitaria Meyer, Florence, Italy. ⁸Mid Yorks NHS Trust, Yorkshire, UK. ⁹Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK. ¹⁰Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK. ¹¹Royal Hospital for Children, Glasgow, Scotland, UK. ¹²Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, PO BOX 30.001, 9700 RB Groningen, The Netherlands. ¹³Centre hospitalier Universitaire de Rennes, Rennes, France. ¹⁴Department of Pediatrics, Regional Centre for Newborn Screening, Diagnosis and Treatment of Inherited Metabolic Diseases and Congenital Endocrine Diseases, University Hospital of Verona, Verona, Italy. ¹⁵Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. ¹⁶Unit of Metabolic Diseases, Choremio Research Laboratory, 1st Department of Paediatrics, University of Athens Medical School, "Aghia Sophia" Children's Hospital, Athens, Greece. ¹⁷Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France. ¹⁸Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. ¹⁹Karolinska University Hospital, Stockholm, Sweden. ²⁰Bradford Teaching Hospital NHS Foundation Trust, Bradford, UK. ²¹Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands. ²²Department of Nutrition and Diet, Gaziantep Cengiz Gökçek Obstetrics and Pediatric Hospital, Gaziantep, Turkey. ²³Ernährungsmedizinische Beratung, Universitätsklinik für Kinder- und Jugendheilkunde, Salzburg, Austria. ²⁴Metabolic Nutrition Clinics. King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. ²⁵Clinic of Paediatric Kidney, Liver and Metabolic Diseases, Medical School Hannover, Hannover, Germany. ²⁶Centro de Referência em Erros Inatos do Metabolismo, Universidade Federal de São Paulo, São Paulo, Brazil. ²⁷Akademiska children's hospital, Uppsala, Sweden. ²⁸Guglielmo Da Saliceto's Hospital, Piacenza, Italy. ²⁹Fondazione MBBM, San Gerardo Hospital, Monza, Italy. ³⁰Centro de Referência de Doenças Hereditárias do Metabolismo, Centro Hospitalar do Porto – CHP, Porto, Portugal. ³¹Centro de Genética Médica, Centro Hospitalar do Porto (CHP), Porto, Portugal. ³²Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal. ³³Centre for Health Technology and Services Research (CINTESIS), Porto, Portugal. ³⁴University Children's Hospital Freiburg, Freiburg, Germany. ³⁵Hospital Regional Universitario Málaga, Málaga, Spain. ³⁶Children's Hospital, University Hospital, Lund, Sweden. ³⁷Academic Medical Center Amsterdam, Amsterdam, Netherlands. ³⁸Sheffield Children's Hospital, Sheffield, UK. ³⁹Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands. ⁴⁰Nutrition Department at International campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Received: 13 October 2017 Accepted: 4 January 2018

Published online: 25 January 2018

References

1. Besley GTN, Walter JH, Lewis MA, Chard CR, Addison GM. Fructose-1,6-bisphosphatase deficiency: severe phenotype with normal leukocyte enzyme activity. *J Inher Metab Dis*. 1994;17:333–5.
2. Baker L, Winegrad AI. Fasting hypoglycaemia and metabolic acidosis associated with deficiency of hepatic fructose-1,6-diphosphatase activity. *Lancet*. 1970;2:13–6.

3. Kikawa Y, Inuzuka M, Jin BY, Kaji S, Koga J, Yamamoto Y, Fujisawa K, Hata I, Nakai A, Shigematsu Y, et al. Identification of genetic mutations in Japanese patients with fructose-1,6-bisphosphatase deficiency. *Am J Hum Genet.* 1997;61:852–61.
4. Steinmann B, Santer R, van den Berghe G. Disorders of Fructose Metabolism. In: Fernandes J, Saudubray J-M, van den Berghe G, Walter JH, editors. *Inborn Metabolic Diseases: Diagnosis and Treatment.* Berlin, Heidelberg: Springer Berlin Heidelberg; 2006. p. 135–42.
5. Morris AA, Deshpande S, Ward-Platt MP, Whitfield AE, Aynsley-Green A, Leonard JV, Pourfarzam M, Bartlett K. Impaired ketogenesis in fructose-1,6-bisphosphatase deficiency: a pitfall in the investigation of hypoglycaemia. *J Inher Metab Dis.* 1995;18:28–32.
6. Herzog B, Wendel U, Morris AA, Eschrich K. Novel mutations in patients with fructose-1,6-bisphosphatase deficiency. *J Inher Metab Dis.* 1999;22:132–8.
7. Beatty ME, Zhang YH, McCabe ER, Steiner RD. Fructose-1,6-diphosphatase deficiency and glyceroluria: one possible etiology for GIS. *Mol Genet Metab.* 2000;69:338–40.
8. Moses SW, Bashan N, Flasterstein BF, Rachmel A, Gutman A. Fructose-1,6-diphosphatase deficiency in Israel. *Isr J Med Sci.* 1991;27:1–4.
9. Tavil B, Sipahi T. Fructose 1,6 diphosphatase deficiency in a Turkish infant. *Eur J Pediatr.* 2003;162:719–20.
10. Faiyaz-Ul-Haque M, Al-Owain M, Al-Dayel F, Al-Hassnan Z, Al-Zaidan H, Rahbeeni Z, Al-Sayed M, Balobaid A, Cluntun A, Toulimat M, et al. Novel FBP1 gene mutations in Arab patients with fructose-1,6-bisphosphatase deficiency. *Eur J Pediatr.* 2009;168:1467–71.
11. Santer R, du Moulin M, Shahinyan T, Vater I, Maier E, Muntau AC, Steinmann B. A summary of molecular genetic findings in fructose-1,6-bisphosphatase deficiency with a focus on a common long-range deletion and the role of MLPA analysis. *Orphanet J Rare Dis.* 2016;11:44.
12. Hommes FA. Inborn errors of fructose metabolism. *Am J Clin Nutr.* 1993;58:788s–95s.
13. Asberg C, Hjalmarson O, Alm J, Martinsson T, Waldenstrom J, Hellerud C. Fructose 1,6-bisphosphatase deficiency: enzyme and mutation analysis performed on calcitriol-stimulated monocytes with a note on long-term prognosis. *J Inher Metab Dis.* 2010;33(Suppl 3):S113–21.
14. Douillard C, Mention K, Dobbelaere D, Wemeau JL, Saudubray JM, Vantghem MC. Hypoglycaemia related to inherited metabolic diseases in adults. *Orphanet J Rare Dis.* 2012;7:26.
15. Mayatepek E, Hoffmann B, Meissner T. Inborn errors of carbohydrate metabolism. *Best Pract Res Clin Gastroenterol.* 2010;24:607–18.
16. Saudubray JM, Baumgartner MR, Walter JH. *Inborn metabolic diseases: diagnosis and treatment.* Berlin Heidelberg: Springer; 2016.
17. Pinto A, Daly A, Evans S, Almeida MF, Assoun M, Belanger-Quintana A, Bernabei S, Bollhalder S, Cassiman D, Champion H, et al. Dietary practices in isovaleric acidemia: a European survey. *Mol Genet Metab Rep.* 2017;12:16–22.
18. Aguiar A, Ahring K, Almeida MF, Assoun M, Belanger Quintana A, Bigot S, Bihet G, Blom Malmberg K, Burlina A, Bushueva T, et al. Practices in prescribing protein substitutes for PKU in Europe: no uniformity of approach. *Mol Genet Metab.* 2015;115:17–22.
19. De Pra M, Laudanna E. Baker-Winegrad disease (hepatomegaly, hypoglycemia during fasting, hyperlactacidemic metabolic acidosis, hepatic fructose-1-6-diphosphatase deficiency). Presentation of the 1st Italian case and pathogenetic hypothesis. *Minerva Pediatr.* 1978;30:1973–86.
20. Matsuura T, Chinen Y, Arashiro R, Katsuren K, Tamura T, Hyakuna N, Ohta T. Two newly identified genomic mutations in a Japanese female patient with fructose-1,6-bisphosphatase (FBPase) deficiency. *Mol Genet Metab.* 2002;76:207–10.
21. Shin YS. Diagnosis of fructose-1,6-bisphosphatase deficiency using leukocytes: normal leukocyte enzyme activity in three female patients. The clinical investigator. 1993;71:115–8.
22. Nitzan O, Saliba WR, Goldstein LH, Elias MS. Fructose-1,6-diphosphatase deficiency: a rare cause of prolonged prothrombin time. *Ann Hematol.* 2004;83:302–3.
23. Krishnamurthy V, Eschrich K, Boney A, Sullivan J, McDonald M, Kishnani PS, Koerber DD. Three successful pregnancies through dietary management of fructose-1,6-bisphosphatase deficiency. *J Inher Metab Dis.* 2007;30:819.
24. Greene HL, Stifel FB, Herman RH. "Ketotic hypoglycemia" due to hepatic fructose-1,6-diphosphatase deficiency: treatment with folic acid. *Am J Dis Child.* 1972;124:415–8.
25. Burlina AB, Poletto M, Shin YS, Zacchello F. Clinical and biochemical observations on three cases of fructose-1,6-diphosphatase deficiency. *J Inher Metab Dis.* 1990;13:263–6.
26. Dixon M, MacDonald A, Stafford J, Portnoi P. Disorders of Carbohydrate Metabolism. In: *Clinical Paediatric Dietetics.* Wiley, Ltd; The Atrium, Southern Gate, Chichester, West Sussex, PO19 85Q, UK. 2015. p. 526–87.
27. Correia CE, Bhattacharya K, Lee PJ, Shuster JJ, Theriaque DW, Shankar MN, Smit GP, Weinstein DA. Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. *Am J Clin Nutr.* 2008;88:1272–6.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

